Carregant...
Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies
This study traces the use of the anticancer drug capecitabine through its loss of patent protection to evaluate the effect of generic pricing on the cost of oral anticancer drugs.
Guardat en:
| Publicat a: | JAMA Intern Med |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Medical Association
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5820701/ https://ncbi.nlm.nih.gov/pubmed/28892541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2017.2788 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|